Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BGM vs IRWD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IRWD Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

IRWD Overall Winner 6-Pillar Tally: BGM 1 – 5 IRWD Matrix Metrics: BGM 4 – 6 IRWD

As of Nov 20, 2026, Ironwood Pharmaceuticals, Inc. - Class A (IRWD) is the stronger overall head-to-head candidate over BGM Group Ltd. Class A (BGM) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BGM carries a Unified Composite Score of 59.6/100 (HOLD) at $8.00 (N/M Forward P/E, -23.4% operating margin), whereas IRWD carries 37.8/100 (SELL) at $4.70 (12.3x Forward P/E, 62.9% operating margin).

  • Composite vs. Pillar Nuance: While BGM currently prints a higher short-term Unified Composite Score (59.6/100 HOLD vs. IRWD 37.8/100 SELL), IRWD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (62.9% vs. -23.4% operating margin) and revenue trajectory (+9.0% vs. +69.8% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BGM vs IRWD
BGM NASDAQ
BGM Group Ltd. Class A Ordinary Shares
Pharmaceutical Preparations
$8.00
-1.6% 1D
Market Cap $108.6M
TTM Revenue $48M
Forward P/E N/M
Beta / 30D Vol 3.69β · 80% Vol
Unified Composite Score
59.6 / 100 HOLD
Tech 65.0 Fund 55.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (167.7% over 20 days), RSI 54
RSI-14: 53.8 · SMA20: $8.51 · SMA50: $5.25
IRWD NASDAQ Head-to-Head Winner
Ironwood Pharmaceuticals, Inc. - Class A
Pharmaceutical Preparations
$4.70
-0.21% 1D
Market Cap $779.7M
TTM Revenue $400M
Forward P/E 12.3x
Beta / 30D Vol 1.23β · 54% Vol
Unified Composite Score
37.8 / 100 SELL
Tech 50.0 Fund 36.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 67
RSI-14: 66.8 · SMA20: $4.24 · SMA50: $4.03

6-Pillar Scorecard Institutional Category Breakdown (BGM 1 – 5 IRWD)

Columns: Metric · BGM · IRWD
1. Valuation Multiples IRWD
Forward P/E N/M 12.3x
Trailing P/E N/M 5.2x
PEG Ratio N/M N/M
EV / Revenue 2.3x 2.6x
2. Growth & Scale IRWD
Revenue Growth (YoY) +69.8% +9.0%
Earnings Growth (YoY) +0.0% +57.0%
TTM Revenue (USD) $48M $400M
Market Cap $108.6M $779.7M
3. Profitability & Quality IRWD
Gross Margin 16.9% 76.4%
Operating Margin -23.4% 62.9%
Net Profit Margin -44.2% 37.4%
Return on Equity (ROE) -7.4% -574.7%
4. Balance Sheet & Cash Flow IRWD
Cash Generation (TTM) -$9.2M EBITDA $205M
Cash Flow Margin -19.3% EBITDA Mgn 51.3%
Net Cash / Leverage $59.55 Book/Sh · -7.4% ROE $250M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning IRWD
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 90.5% (30th %ile)
Put/Call OI Skew N/A 0.02x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat BGM
OpEx & R&D Intensity 40.3% of Rev ($19M) 13.5% of Rev ($54M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BGM (4) vs IRWD (6)
Institutional Metric BGM IRWD Criterion Row Edge
Market Capitalization
Scale
$108.6M $779.7M Larger Scale IRWD
Trailing P/E Ratio
Valuation
N/M 5.2x Lower Multiple IRWD
Forward P/E Ratio
Valuation
N/M 12.3x Lower Multiple IRWD
Revenue Growth (YoY)
Growth
+69.8% +9.0% Higher Growth BGM
Operating Margin (TTM)
Profitability
-23.4% 62.9% Higher Margin IRWD
Net Profit Margin
Profitability
-44.2% 37.4% Higher Margin IRWD
Return on Equity (ROE)
Capital Efficiency
-7.4% -574.7% Higher ROE BGM
52-Week Range Position
Momentum
74% ($0–$11) 62% ($3–$6) Stronger Trend BGM
Beta / 30D Volatility
Risk Regime
3.69β · 80% Vol 1.23β · 54% Vol Lower Realized Risk IRWD
Unified Institutional Score
Composite Signal
59.6 / 100 (HOLD) 37.8 / 100 (SELL) Higher Composite BGM
Trailing 12M Revenue (USD)
Operating Scale
$48M $400M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
16.9% 76.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.3x EV/Rev N/M PEG · 2.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.2M EBITDA ($59.55 Book/Sh · -7.4% ROE) $205M ($250M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IRWD +46.84 pp
BGM: -21.57% · IRWD: +25.27%
3M Horizon BGM +2664.9 pp
BGM: +2673.93% · IRWD: +9.03%
6M Horizon BGM +2947.63 pp
BGM: +2962.79% · IRWD: +15.16%
1Y Horizon IRWD +53.88 pp
BGM: -5.77% · IRWD: +48.11%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BGM vs IRWD. Trailing 12-month operating profitability (BGM -23.4% vs IRWD 62.9%) and valuation multiples (BGM N/M vs IRWD 12.3x Forward P/E) are benchmarked directly in Pillar 4 below.

BGM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$48M
Gross Margin16.9%
Op. Margin-23.4%
ROE / Fwd P/E-7.4% · N/M
IRWD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$400M
Gross Margin76.4%
Op. Margin62.9%
ROE / Fwd P/E-574.7% · 12.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BGM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BGM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IRWD CONSOLIDATION
138d in phase · OBV NEUTRAL
Current IV 90.5%
IV Percentile 30th %ile
Put/Call OI Skew 0.02x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact IRWD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BGM Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $108.6M market capitalization and -23.4% operating margin.
OpEx & R&D Reinvestment 40.3% of Rev ($19M)
90D Engineering Disclosures 0 Published
IRWD Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $779.7M market capitalization and 62.9% operating margin.
OpEx & R&D Reinvestment 13.5% of Rev ($54M)
90D Engineering Disclosures 0 Published

Investor FAQ BGM vs IRWD Key Questions & Quantitative Answers

As of Nov 20, 2026, Ironwood Pharmaceuticals, Inc. - Class A (IRWD) is the stronger overall head-to-head candidate over BGM Group Ltd. Class A (BGM) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BGM carries a Unified Composite Score of 59.6/100 (HOLD) at $8.00 (N/M Forward P/E, -23.4% operating margin), whereas IRWD carries 37.8/100 (SELL) at $4.70 (12.3x Forward P/E, 62.9% operating margin). Composite vs. Pillar Nuance: While BGM currently prints a higher short-term Unified Composite Score (59.6/100 HOLD vs. IRWD 37.8/100 SELL), IRWD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (62.9% vs. -23.4% operating margin) and revenue trajectory (+9.0% vs. +69.8% YoY).

IRWD leads the Growth & Scale pillar: BGM posts +69.8% YoY revenue growth and +0.0% YoY earnings growth on $48M TTM revenue (16.9% gross margin, -23.4% operating margin), compared with IRWD at +9.0% YoY revenue growth and +57.0% YoY earnings growth on $400M TTM revenue (76.4% gross margin, 62.9% operating margin). On trailing 12-month operating scale, BGM generates $48M in USD-normalized revenue versus $400M for IRWD. In operating R&D and SG&A reinvestment, BGM deploys 40.3% of Rev ($19M) (0 90-day corporate R&D disclosures) versus 13.5% of Rev ($54M) (0 disclosures) for IRWD.

IRWD screens cheaper on headline valuation multiples. BGM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.3x EV/Revenue (-19.3% EBITDA margin), whereas IRWD trades at 12.3x Forward P/E, 5.2x Trailing P/E, N/M PEG, and 2.6x EV/Revenue (51.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BGM (-7.4% ROE) versus IRWD (-574.7% ROE) capital efficiency.

In options market volatility and institutional positioning, BGM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (3.69β · 80% Vol realized risk). By comparison, IRWD carries 90.5% implied volatility (30th %ile, Balanced (25th–60th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.23β · 54% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.